DG Peptide Protocols
Well StudiedWeight LossGrowth Hormone

GHRP-2

Pralmorelin

Growth Hormone Releasing Peptide-2 | Pralmorelin

Half-life
~30 minutes
Chain length
6 amino acids
Reference frequency
2-3x daily

Research overview

DoseGear research brief

GHRP-2 is a synthetic growth hormone secretagogue that stimulates the pituitary gland to release growth hormone. It is one of the most potent members of the GHRP family, being 2-3 times more effective than GHRP-6 in stimulating GH release. Originally developed as a diagnostic agent for growth hormone deficiency, it works by mimicking ghrelin and binding to the GHS-R1a receptor.

Mechanism of action

GHRP-2 acts as a synthetic agonist of ghrelin, binding to the growth hormone secretagogue receptor (GHS-R1a) in the hypothalamus and pituitary. This stimulates cAMP production and promotes pulsatile release of endogenous growth hormone without suppressing natural feedback loops. It works synergistically with GHRH to amplify GH secretion beyond what either peptide achieves alone.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Synthetic growth-hormone-releasing peptide investigated diagnostically and pharmacologically.

What it is researched for

Growth-hormone secretion and pituitary-function research through ghrelin/GHS-R1a agonism.

Research observation window

No sourced clinical-benefit response window is reported.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research contextAmountFrequencyRoute
GH optimization100-150 mcg2-3x dailySubQ
Enhanced results200-300 mcg2-3x dailySubQ
With GHRH (synergy)100 mcg each2-3x dailySubQ (combined)
Pre-sleep protocol100-200 mcgBefore bedSubQ

Reference cycle

8-12 weeks

Reference storage

2-8°C refrigerated

Safety context

Reported side effects

  • Increased appetite (less than GHRP-6)
  • Mild water retention
  • Tingling or numbness in extremities
  • Tiredness or lethargy after injection
  • Mild headache

Contraindications & cautions

  • Active cancer or history of cancer
  • Pregnancy or breastfeeding
  • Pituitary disorders
  • Diabetic retinopathy
  • WADA prohibited for competitive athletes

Scientific references

  1. 01

    Growth Hormone Releasing Peptide-2 increases food intake in healthy men

    Scientific citationGrowth Hormone Releasing Peptide-2 increases food intake in healthy men. Journal of Clinical Endocrinology & Metabolism (2010).
  2. 02

    Synthetic Growth Hormone-Releasing Peptides: Cytoprotective Effects

    Scientific citationSynthetic Growth Hormone-Releasing Peptides: Cytoprotective Effects. Clinical Medicine Insights: Cardiology (2017).
  3. 03

    GHRP-2 effects on growth hormone release in swine

    Scientific citationGHRP-2 effects on growth hormone release in swine. Domestic Animal Endocrinology (2000).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles